HRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
HRAS mutation
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A2 - Guideline
|
cabozantinib capsule Sensitive: A2 - Guideline
|
HRAS mutation
|
SCCHN
|
HRAS mutation
|
SCCHN
|
tipifarnib Sensitive: B - Late Trials
|
tipifarnib Sensitive: B - Late Trials
|
HRAS mutation
|
Urothelial Cancer
|
HRAS mutation
|
Urothelial Cancer
|
tipifarnib Sensitive: C2 – Inclusion Criteria
|
tipifarnib Sensitive: C2 – Inclusion Criteria
|
HRAS mutation
|
Thyroid Gland Carcinoma
|
HRAS mutation
|
Thyroid Gland Carcinoma
|
trametinib Sensitive: C2 – Inclusion Criteria
|
trametinib Sensitive: C2 – Inclusion Criteria
|
HRAS mutation
|
Multiple Myeloma
|
HRAS mutation
|
Multiple Myeloma
|
selinexor Sensitive: C3 – Early Trials
|
selinexor Sensitive: C3 – Early Trials
|
HRAS mutation
|
AML
|
HRAS mutation
|
AML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
HRAS mutation
|
AML
|
HRAS mutation
|
AML
|
venetoclax + ABBV-621 Sensitive: C3 – Early Trials
|
venetoclax + ABBV-621 Sensitive: C3 – Early Trials
|
HRAS mutation
|
Salivary Gland Cancer
|
HRAS mutation
|
Salivary Gland Cancer
|
tipifarnib Sensitive: C3 – Early Trials
|
tipifarnib Sensitive: C3 – Early Trials
|
HRAS mutation
|
SCCHN
|
HRAS mutation
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
HRAS mutation
|
Thyroid Gland Anaplastic Carcinoma
|
HRAS mutation
|
Thyroid Gland Anaplastic Carcinoma
|
atezolizumab + cobimetinib Sensitive: C3 – Early Trials
|
atezolizumab + cobimetinib Sensitive: C3 – Early Trials
|
HRAS mutation
|
Solid Tumor
|
HRAS mutation
|
Solid Tumor
|
selumetinib Resistant: C3 – Early Trials
|
selumetinib Resistant: C3 – Early Trials
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
|
HRAS mutation
|
Melanoma
|
HRAS mutation
|
Melanoma
|
cobimetinib + HM95573 Sensitive: C3 – Early Trials
|
cobimetinib + HM95573 Sensitive: C3 – Early Trials
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
bevacizumab Resistant: C3 – Early Trials
|
bevacizumab Resistant: C3 – Early Trials
|
HRAS mutation
|
Rectal Cancer
|
HRAS mutation
|
Rectal Cancer
|
SOXIRI Sensitive: C3 – Early Trials
|
SOXIRI Sensitive: C3 – Early Trials
|
HRAS mutation
|
Rectal Cancer
|
HRAS mutation
|
Rectal Cancer
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
HRAS mutation
|
AML
|
HRAS mutation
|
AML
|
mTOR inhibitor Resistant: D – Preclinical
|
mTOR inhibitor Resistant: D – Preclinical
|
HRAS mutation
|
Rhabdomyosarcoma
|
HRAS mutation
|
Rhabdomyosarcoma
|
tipifarnib Sensitive: D – Preclinical
|
tipifarnib Sensitive: D – Preclinical
|
HRAS mutation
|
Endometrial Cancer
|
HRAS mutation
|
Endometrial Cancer
|
AZ 628 Sensitive: D – Preclinical
|
AZ 628 Sensitive: D – Preclinical
|
HRAS mutation
|
Endometrial Cancer
|
HRAS mutation
|
Endometrial Cancer
|
PD-0325901 Sensitive: D – Preclinical
|
PD-0325901 Sensitive: D – Preclinical
|
HRAS mutation
|
Bladder Cancer
|
HRAS mutation
|
Bladder Cancer
|
FL118 Sensitive: D – Preclinical
|
FL118 Sensitive: D – Preclinical
|